Effect of prostaglandin E1 on peritoneal membrane transport in CAPD-treated diabetic patients.
Jaroszynski
Andrzej J
AJ
Nephrology Medical University of Lublin Lublin, Poland. jaroszynskiaj@interia.pl
Ksiazek
Andrzej
A
D000527:Alprostadil / Q000494:pharmacology*; D001692:Biological Transport / Q000187:drug effects; D003928:Diabetic Nephropathies / Q000378:metabolism* / Q000628:therapy*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism* / Q000628:therapy*; D046911:Macromolecular Substances / Q000378:metabolism; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D010530:Peritoneal Dialysis; D010531:Peritoneal Dialysis, Continuous Ambulatory; D010537:Peritoneum / Q000378:metabolism*; D014665:Vasodilator Agents / Q000494:pharmacology*
D046911:Macromolecular Substances; D014665:Vasodilator Agents; D000527:Alprostadil